What MACI is designed to treat

Articular cartilage — the smooth, load-bearing surface lining the ends of the bones in your knee — does not repair itself reliably when damaged. MACI (Matrix-induced Autologous Chondrocyte Implantation) is a well-established surgical technique designed to fill a specific kind of damage: a focal, full-thickness cartilage defect, meaning a discrete patch where the cartilage has worn all the way down to bone (classified as ICRS or Outerbridge Grade 3–4). The most common sites treated are the medial femoral condyle — the inner knuckle of the thigh bone — and the patellofemoral joint beneath the kneecap.

What distinguishes MACI from older marrow-stimulation techniques such as microfracture is the quality of the tissue it produces. Microfracture stimulates the body to fill the defect with fibrocartilage, a scar-like substitute that tends to break down within two to three years. MACI, by contrast, grows hyaline-like cartilage — structurally closer to the original tissue — from the patient's own cells.

This also defines its limits. MACI addresses a focal problem. Where arthritis has spread across the whole joint surface, regenerating every affected area is, in clinical terms, very difficult, almost impossible. Diffuse, whole-knee osteoarthritis is a contraindication, and those patients are better served by a different pathway entirely.

The patient profile most likely to benefit

Defect size is the most immediate filter. For lesions under roughly 2–4 cm², simpler single-stage procedures — microfracture or mosaicplasty — remain clinically reasonable, carrying lower procedural complexity and a shorter rehabilitation pathway. Once a defect reaches approximately 3 cm² or more, the balance shifts in MACI's favour: the SUMMIT randomised controlled trial found meaningfully better KOOS pain and function scores for MACI compared with microfracture at both two and five years in this size range. That advantage becomes more pronounced as lesion size grows, and MACI carries no theoretical upper limit for focal defects — making it particularly well suited to large or geometrically complex lesions where other techniques run out of road.

Patient age is the second axis, but it is not a hard boundary. Clinical teams generally consider candidates up to around 40–45 years, yet the more relevant measure is biological age: bone quality, overall cartilage health across the joint, and healing capacity matter more than the year on a birth certificate. An active, otherwise healthy person in their late forties may be a stronger candidate than a sedentary, metabolically compromised thirty-five-year-old.

The third requirement is a joint capable of supporting the graft. Candidates need adequate bone stock beneath the defect, minimal cartilage wear in the surrounding compartments, and no inflammatory arthritis — conditions that would undermine graft integration regardless of technical execution. A co-existing mechanical problem, such as varus malalignment or ligamentous instability, does not automatically exclude a patient, but it must be corrected surgically at the same sitting; unaddressed loading abnormalities significantly reduce the likelihood of a durable outcome.

Mechanical problems that must be corrected first

A cartilage graft placed in a knee that still loads unevenly is subject to forces it was never designed to survive. If the tibia tilts inward — varus malalignment — weight concentrates on the medial compartment, precisely where MACI defects most commonly arise. If the kneecap tracks incorrectly, a patellofemoral graft faces the same adverse pressure. In either case, the implanted tissue deteriorates faster, and the clinical benefit is reduced regardless of how well the procedure itself was performed.

Co-existing mechanical problems are therefore treated as prerequisites rather than optional extras. The most common correction for varus malalignment is a high tibial osteotomy (HTO), which realigns the weight-bearing axis across the joint. Patellofemoral instability may require a tibial tubercle transfer; ligamentous laxity — such as an unstable ACL — typically requires reconstruction. These procedures are usually carried out at the same surgical sitting as MACI or, in more complex cases, staged beforehand.

A thorough pre-operative assessment identifies which, if any, of these corrections apply. Where they are needed, they add procedural complexity and influence the overall recovery timeline — factors that a specialist will discuss in detail once imaging and clinical examination are complete.

Clinical outcomes: pain, function, and how long results last

Reported outcomes paint a consistently positive picture for suitable candidates. In a cohort of 150 patients who underwent ACI or MACI, 85% expressed satisfaction with their functional ability after surgery — a figure that sits well above typical thresholds for surgical success in joint procedures.

The SUMMIT randomised controlled trial, already noted for its role in guiding defect-size selection, also provides the clearest head-to-head durability data: KOOS pain and function scores remained meaningfully higher in the MACI group than in the microfracture group at both two and five years. MRI evidence at the five-year mark shows good cartilage fill correlating with those sustained clinical improvements, suggesting the scaffold is producing structurally useful tissue rather than merely masking symptoms.

Longer-term data are now available. A minimum ten-year outcome study of ACI — awarded the John Insall Award — and separate five-year clinical and MRI follow-up from Ebert et al. together indicate that most patients in long-term series maintained improved pain and function scores well beyond the medium-term window. It is worth being precise, however: robust evidence beyond ten years remains limited, and the data continue to accumulate. Outcomes for patellofemoral defects are also less well characterised than those for the femoral condyle.

The contrast with microfracture is clinically meaningful and helps contextualise MACI's higher procedural cost. Published series show significant score deterioration between 18 and 36 months following microfracture, and some cohorts report survivorship below 60% at three years. For patients whose priorities centre on durable, long-term restoration rather than short-term symptom relief, this difference in trajectory is material.

Return to sport: what the evidence shows

For many patients, the defining question is not whether pain will improve but whether they will be able to play sport again. On this point, MACI compares favourably with other cartilage restoration procedures: published series place its return-to-sport rates among the highest of any technique currently in use.

The most detailed sport-specific data come from competitive football cohorts. In these series, 83% of competitive players returned to sport after MACI or ACI; 80% reached the same competitive level they had played at before injury; and between 87% and 100% maintained the ability to play at five years. These are meaningful numbers — but they require honest context. The figures derive from cohort studies in competitive athletic populations, not randomised controlled trials, and data for recreational athletes and less active patients are less precisely quantified. The evidence is strongest for competitive sport; outcomes for recreational activity and everyday physical function are generally positive but not as well characterised.

Timeline matters too. Return to sport typically falls in the 12–18 month range, and this reflects cartilage biology rather than procedural difficulty: the implanted scaffold takes time to mature into load-bearing tissue, and loading it prematurely risks disrupting that process. Where concurrent mechanical corrections such as a high tibial osteotomy or tibial tubercle transfer were performed, rehabilitation planning will account for those additional variables as well.

Emerging options and deciding whether to pursue MACI

Beyond the established two-stage pathway, a single-stage variant known as STACi combines biopsy and reimplantation in one surgical sitting, using a mix of the patient's own chondrocytes and bone marrow-derived mesenchymal stem cells on a collagen scaffold. The practical appeal is straightforward: reduced waiting time and one fewer operation. STACi is currently considered most suitable for younger patients, typically under 45, but comparative data against conventional two-stage MACI are still maturing, and direct outcome comparisons between the two approaches should be treated with caution. PRP augmentation is under investigation as a potential enhancer of graft quality when used alongside either technique; the evidence is early-stage and it is not yet established as standard practice.

On cost, MACI carries higher upfront expenditure than microfracture, but health-economic analyses generally support its cost-effectiveness for larger defects given the lower long-term revision burden.

Of the candidacy factors covered in this article, defect size tends to be the most objectively decisive — it is what separates the patient likely to do well with marrow stimulation from the one who needs a cell-based scaffold for durable results. The commonest reason MACI proves unsuitable at assessment is not age or activity level, but diffuse rather than focal cartilage loss: a distinction that imaging and clinical examination can usually clarify at an early stage. Search MSK lists cartilage restoration specialists across the UK — filter by region and specialty to find one suited to your situation. Knowing where a specific defect falls on that focal-to-diffuse spectrum is the most practical first step toward a well-matched treatment plan.